Verici Dx, a company developing advanced clinical diagnostics for organ transplant, has entered into a global licensing partnership with healthcare giant Thermo Fisher to develop an assay for pre-transplant kidney testing.
With so many advanced therapies on the horizon, the next few years are poised to be one of significant progress for patients with over 2000 cell and gene therapies in active clinical trials globally.
The company opens a bioanalytical lab in the US, which offers an additional 59,000-square-feet of space to the overall facility, making it “one of the largest laboratories of its kind.”
A $76m investment in the facility in Grand Island, New York, will increase capacity to produce raw materials used in manufacture of vaccines and biologic therapies.
Thermo Fisher Scientific says its is leveraging the company’s global infrastructure to offer end-to-end services aimed at speeding up the introduction of cell and gene therapies.
Moderna and Thermo Fisher Scientific have announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing of COVID-19 vaccine Spikevax in the US, as well as other investigational mRNA vaccines and therapies.
Thermo Fisher Scientific doubles the capacity of its gene therapy and viral vector processing facility in Alachua, Florida, to provide scalability to customers.
Regardless of the quality of the raw materials used in bioproduction processes, variability is a very common threat that can be addressed, says Thermo Fisher executive.
Thermo Fisher and Scinogy partner to improve scalability and cost-effectiveness of cell and gene therapy manufacture through the addition of the former’s centrifuge.
Thermo Fisher Scientific bolsters its gene therapy capabilities by acquiring Brammer Bio for $1.7bn, as the market becomes an ‘increasing focus’ for customers.
Bioprocessing suppliers have recently expressed optimism in the sector despite a slowdown in growth, and one expert believes this will drive investment in new tech and markets.
Thermo Fisher says Patheon will become the most competitive biologics CDMO in the market through direct access to its bioprocessing technologies and capabalities.
Integrating single-use, automation and continuous processing equipment will be the future for bioproduction says Thermo Fisher acquisition Finesse Solution.
A WuXi Biologics facility tipped to be the world’s largest single-use mammalian cell culture site will be equipped with disposable systems from Thermo Fisher.
Mab-Venture Biopharma has entered a collaboration to establish an antibody development and production plant in China incorporating Thermo Fisher’s single-use bioreactors and SmartFactory automated technology.
Price hikes and lack of innovation, or better buying power and end-to-end services? Experts are split on supplier M&A and its effect on biomanufacturers.
Thermo Fisher Scientific says it is buying Finesse Solutions, its long-term supplier of measurement and control solutions for bioprocessing applications.
South Korea is a key opportunity for biopharma services firms says Thermo Fisher, reporting its third quarter which saw it up capabilities in the region.
Increased biologics both on the market and in development and demand for greater manufacturing efficiencies have led to another strong quarter for Thermo Fisher.
Adaptimmune has entered into a new 10-year development and supply agreement for use of thermos Fisher’s Dynabeads CD3/CD28 CTS T-cell isolation, activation and expansion technology.
Danaher's acquisition of Pall will not change the competitive landscape in the bioprocessing tech industry says Thermo Fisher, as it earmarks $10bn for further M&A activity.
The acquisition of Pall Corporation by either Thermo Fisher or Danaher could spur further M&A in the life science tech industry, according to an analyst.
The biopharma services market keeps expanding and “growth prospects look fabulous,” says Thermo Fisher, reporting better than expected sales across its Life Sciences business for the second quarter 2014.
Thermo Fisher Scientific has licensed rights to gene editing technology for bioproduction applications that it claims targets DNA more precisely and reliably than current approaches.
Q1 revenues for Thermo Fisher’s Life Sciences Solutions business shot up 384% year-over-year in a quarter that saw the integration of Life Technologies.
An analyst predicts overlap between Thermo Fisher and Life Technologies will present manufacturing, procurement and logistics cost-saving opportunities.
Chinese authorities have given Thermo Fisher Scientific the green light to buy Life Technologies on the condition it discounts certain products sold in the coutry.
